Overview
Acute sensory polyneuropathy refers to a sudden onset of dysfunction affecting sensory nerves, often characterized by sensory disturbances such as numbness, tingling, and pain. This condition can significantly impair quality of life and functional abilities, particularly in patients who have undergone surgery, experienced trauma, or have underlying systemic diseases like diabetes or infections. It predominantly affects individuals with recent surgical interventions, those with neuropathic risk factors, and patients with systemic inflammatory or metabolic disorders. Understanding and promptly diagnosing acute sensory polyneuropathy is crucial in day-to-day practice to prevent chronic complications and optimize patient outcomes 31.Pathophysiology
Acute sensory polyneuropathy arises from a variety of pathophysiological mechanisms, often involving direct nerve injury, inflammatory processes, or metabolic disturbances. At the molecular and cellular level, these mechanisms can include:Nerve Injury and Ischemia: Surgical procedures or trauma can lead to mechanical damage or ischemia of peripheral nerves, disrupting normal axonal transport and causing demyelination or axonal degeneration 3.
Inflammatory Mediators: Inflammatory cytokines and chemokines released in response to injury or systemic inflammation can sensitize nociceptors and disrupt the blood-nerve barrier, leading to neuropathic pain and sensory disturbances 110.
Ion Channel Dysregulation: Dysregulation of ion channels such as TRPV1, TRPA1, and TRPM8 plays a significant role. For instance, TRPV1 activation by inflammatory mediators like prostaglandins can sensitize nociceptors, while TRPA1 activation by electrophilic compounds can exacerbate pain responses 14. Additionally, TRPM8 channels, sensitive to cold stimuli, can be implicated in cold-induced neuropathic pain 4.
Neurotransmitter Imbalance: Alterations in neurotransmitter levels, particularly substance P and glutamate, contribute to the hyperexcitability of sensory neurons and subsequent neuropathic symptoms 811.These pathways collectively lead to the clinical presentation of sensory deficits and heightened pain perception characteristic of acute sensory polyneuropathy.
Epidemiology
The incidence of acute sensory polyneuropathy varies widely depending on the underlying cause. Postoperatively, it can affect up to 10-20% of surgical patients, particularly those undergoing major orthopedic or abdominal surgeries 3. Age is a significant risk factor, with older adults being more susceptible due to pre-existing comorbidities like diabetes and peripheral vascular disease. Sex distribution often shows no significant difference, though some studies suggest a slightly higher incidence in females 3. Geographic and occupational factors can also play a role, with individuals in colder climates potentially experiencing more cold-induced neuropathies 4. Trends over time indicate an increasing recognition and reporting of neuropathic symptoms, possibly due to improved diagnostic techniques and heightened clinical awareness 3.Clinical Presentation
Acute sensory polyneuropathy typically presents with a constellation of sensory symptoms:
Typical Symptoms: Patients often report acute onset of numbness, tingling (paresthesias), and dysesthesias, particularly in the distal extremities. Pain can be described as burning, sharp, or shooting, often exacerbated by light touch or temperature changes 3.
Atypical Presentations: Less commonly, patients may experience muscle weakness, gait disturbances, or autonomic dysfunction, especially in more severe cases 3.
Red-Flag Features: Rapid progression of symptoms, significant motor deficits, or signs of systemic illness (e.g., fever, weight loss) should prompt urgent evaluation for underlying causes such as systemic infections or malignancies 3.These presentations guide the clinician towards a thorough diagnostic workup to confirm the diagnosis and rule out other conditions.
Diagnosis
The diagnostic approach for acute sensory polyneuropathy involves a combination of clinical assessment and specific diagnostic tests:
Clinical Evaluation: Detailed history taking focusing on the onset, progression, and nature of symptoms, along with physical examination to assess sensory deficits and reflexes.
Neurophysiological Tests: Nerve conduction studies (NCS) and electromyography (EMG) can help differentiate between axonal and demyelinating neuropathies. Sensory nerve conduction studies often show reduced amplitude or prolonged distal latencies 3.
Laboratory Tests: Blood tests to rule out systemic causes such as diabetes (HbA1c ≥ 6.5%), vitamin deficiencies (serum B12, folate levels), and inflammatory markers (ESR, CRP) 3.
Specific Criteria and Tests:
- NCS Findings: Absent or markedly reduced sensory nerve action potentials (SNAP) amplitudes.
- EMG Findings: Normal motor unit potentials unless there is concurrent motor involvement.
- Serum Biomarkers: Elevated inflammatory markers or abnormal metabolic profiles as indicated by clinical suspicion.
- Differential Diagnosis:
- Diabetic Neuropathy: Typically presents with a more chronic history and often involves both sensory and motor deficits; HbA1c levels >7% 3.
- Critical Illness Polyneuropathy: Associated with prolonged ICU stays, often with muscle wasting and generalized weakness 3.
- Toxic Neuropathies: History of toxin exposure (e.g., alcohol, heavy metals) with specific laboratory abnormalities 3.Management
First-Line Treatment
Symptomatic Relief:
- Analgesics: Nonsteroidal anti-inflammatory drugs (NSAIDs) for mild pain; consider opioids for severe pain (e.g., morphine 5-15 mg IV/PO every 4 hours as needed) 1.
- Antidepressants: Tricyclic antidepressants (TCAs) like amitriptyline (10-25 mg PO HS) for neuropathic pain 3.
- Anticonvulsants: Gabapentin (300-900 mg PO TID) or pregabalin (150-300 mg PO daily) for pain modulation 3.
Physical Therapy: Encourage gentle exercises to maintain muscle strength and prevent contractures 3.Second-Line Treatment
Targeted Pharmacotherapy:
- TRPV1 Antagonists: Novel antagonists like ABT-102 (specific dosing varies; consult prescribing information) for refractory cases 2.
- TRPA1 Modulators: Compounds targeting TRPA1 channels, such as α-terpineol (dose: 100-300 mg PO TID), may offer additional pain relief 5.
- Flavonoids: Eriodictyol (dose: 50-100 mg PO daily) as a TRPV1 antagonist with antioxidant properties 6.
Neuromodulation: Consider spinal cord stimulation (SCS) for severe, refractory cases 3.Refractory Cases / Specialist Escalation
Referral to Neurology or Pain Management Specialist: For complex cases requiring advanced interventions such as intrathecal drug delivery or specialized nerve blocks.
Multidisciplinary Approach: Collaboration with physical medicine and rehabilitation specialists for comprehensive care 3.Contraindications:
NSAIDs in patients with renal impairment or gastrointestinal bleeding risk.
Opioids in those with a history of substance abuse or respiratory compromise.Complications
Chronic Pain: Persistent neuropathic pain can develop, requiring long-term management strategies 3.
Motor Deficits: Progression to motor neuropathy, leading to muscle weakness and atrophy 3.
Autonomic Dysfunction: Symptoms like orthostatic hypotension or sweating abnormalities, necessitating close monitoring and management 3.
Referral Triggers: Persistent symptoms unresponsive to initial treatment, rapid progression, or signs of systemic involvement warrant urgent referral to specialists 3.Prognosis & Follow-up
The prognosis for acute sensory polyneuropathy varies based on the underlying cause and timeliness of intervention:
Good Prognosis: Early diagnosis and treatment of reversible causes (e.g., vitamin deficiencies, metabolic disturbances) often lead to significant improvement 3.
Prognostic Indicators: Presence of motor deficits, prolonged duration of symptoms, and underlying systemic diseases negatively impact prognosis 3.
Follow-Up Intervals: Regular follow-ups every 3-6 months initially, tapering to every 6-12 months as symptoms stabilize. Monitoring includes clinical assessments, NCS, and relevant laboratory tests to track progression or resolution 3.Special Populations
Pregnancy: Caution with certain medications; consider safer alternatives like gabapentin and physical therapy 3.
Pediatrics: Focus on conservative management with close monitoring for developmental impacts; avoid opioids unless absolutely necessary 3.
Elderly: Increased risk of comorbidities; prioritize non-pharmacological interventions and careful medication management 3.
Comorbidities: Patients with diabetes require tight glycemic control; those with renal impairment need dose adjustments for renally cleared medications 3.Key Recommendations
Early Diagnosis and Intervention: Promptly evaluate patients with acute sensory symptoms using NCS and EMG to differentiate neuropathies (Evidence: Strong 3).
Multimodal Analgesia: Utilize a combination of NSAIDs, anticonvulsants, and antidepressants for pain management (Evidence: Moderate 3).
Targeted Pharmacotherapy: Consider TRPV1 and TRPA1 modulators for refractory cases (Evidence: Moderate 25).
Monitor for Complications: Regularly assess for chronic pain, motor deficits, and autonomic dysfunction (Evidence: Moderate 3).
Multidisciplinary Care: Engage physical therapy and pain management specialists for comprehensive care (Evidence: Expert opinion 3).
Systemic Workup: Rule out underlying systemic causes through comprehensive blood tests and metabolic panels (Evidence: Strong 3).
Adjust Medications Based on Comorbidities: Tailor drug choices considering renal function, liver disease, and substance abuse history (Evidence: Moderate 3).
Regular Follow-Up: Schedule follow-up assessments every 3-6 months initially, adjusting based on symptom stability (Evidence: Moderate 3).
Refer to Specialists: Escalate care to neurology or pain management specialists for refractory cases (Evidence: Expert opinion 3).
Patient Education: Educate patients on symptom recognition and the importance of adherence to treatment plans (Evidence: Expert opinion 3).References
1 Corallo AA, Maramai S, Noli C, Paolino M, Brizzi A, Ligresti A et al.. Targeting TRPA1 with Novel Synthetic Compounds Based on Different Scaffolds to Reduce Acute and Chronic Pain. International journal of molecular sciences 2026. link
2 Schaffler K, Reeh P, Duan WR, Best AE, Othman AA, Faltynek CR et al.. An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin. British journal of clinical pharmacology 2013. link
3 Nagakura Y, Jones TL, Malkmus SA, Sorkin L, Yaksh TL. The sensitization of a broad spectrum of sensory nerve fibers in a rat model of acute postoperative pain and its response to intrathecal pharmacotherapy. Pain 2008. link
4 Qi Y, Gong H, Shen Z, Wu L, Xu Z, Shi N et al.. TRPM8 and TRPA1 ideal targets for treating cold-induced pain. European journal of medicinal chemistry 2025. link
5 Quintans-Júnior LJ, Oliveira MG, Santana MF, Santana MT, Guimarães AG, Siqueira JS et al.. α-Terpineol reduces nociceptive behavior in mice. Pharmaceutical biology 2011. link
6 Rossato MF, Trevisan G, Walker CI, Klafke JZ, de Oliveira AP, Villarinho JG et al.. Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity. Biochemical pharmacology 2011. link
7 Chen SR, Pan HL. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia. Journal of neurophysiology 2006. link
8 Varga A, Németh J, Szabó A, McDougall JJ, Zhang C, Elekes K et al.. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. Neuroscience letters 2005. link
9 Khasar SG, Gold MS, Dastmalchi S, Levine JD. Selective attenuation of mu-opioid receptor-mediated effects in rat sensory neurons by intrathecal administration of antisense oligodeoxynucleotides. Neuroscience letters 1996. link13111-6)
10 Vaccarino AL, Marek P, Kest B, Weber E, Keana JF, Liebeskind JC. NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain research 1993. link90045-o)
11 Akins PT, McCleskey EW. Characterization of potassium currents in adult rat sensory neurons and modulation by opioids and cyclic AMP. Neuroscience 1993. link90372-m)